Crizonix (XALKORI) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
DOSAGE AND ADMINISTRATION
1.Recommended Dose: 250 mg orally twice daily.
2.Moderate Hepatic Impairment: 200 mg orally twice daily.
3.Severe Hepatic Impairment: 250 mg orally once daily.
4.Severe Renal Impairment: 250 mg orally once daily.